When the COVID pandemic hit, the Texas Therapeutics Institute sprung into action to develop therapies for patients suffering from the virus. Not only have they developed drugs to help fight COVID, but they are also developing neurological drugs to help combat diseases like Alzheimer's.
A newly developed agonistic antibody reduced the amyloid pathology in mice with Alzheimer’s disease, signaling its promise as a potential treatment for the disease, according to a team of researchers at UTHealth Houston.
The ultrastructural morphology exhibited by the 2019 Novel Coronavirus (2019-nCoV), which was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China, is seen in an illustration released by...
GSBS faculty member Zhiqiang An, PhD, has been named a fellow of the National Academy of Inventors (NAI), the organization announced Dec. 7. The NAI Fellows Program highlights academic inventors who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society. Election to NAI Fellow is the highest professional distinction accorded solely to academic inventors.
Scientists have identified a protein that may help prevent immune cells from entering breast tumors and killing the cancer cells. The research, which was conducted primarily in mice, could lead to potential strategies for overcoming barriers that keep certain immune cells from attacking tumors, according to the investigators.
Research from the lab of Kyoji Tsuchikama, PhD, assistant professor in the Texas Therapeutics Institute at The Brown Foundation Institute of Molecular Medicine, on a new potential treatment for combating breast cancer has been published in the June edition of Nature Communications.
There are now several monoclonal antibodies, identical copies of a therapeutic antibody produced in large numbers, that are authorized for the treatment of COVID-19. But in the ongoing effort to beat this terrible pandemic, there’s plenty of room for continued improvements in treating infections with SARS-CoV-2, the virus that causes COVID-19.
A possible explanation for why many cancer drugs that kill tumor cells in mouse models won’t work in human trials has been found by researchers with The University of Texas Health Science Center at Houston (UTHealth) School of Biomedical Informatics and McGovern Medical School.
Researchers at The University of Texas Health Science Center at Houston (UTHealth) and The University of Texas Medical Branch at Galveston (UTMB Health) have discovered a potential new antibody therapy for COVID-19. The study was published in Nature Communications.
The annual symposium of the CPRIT Therapeutic Antibody Core took place on Friday, December 11, 2020, from 1:00 pm Central Time. For the safety of participants during the COVID-19 pandemic, the symposium was held online via WebEx. Speakers highlighted the core’s capacities and provided examples of successful core collaborations.
The annual symposium of the CPRIT Therapeutic Antibody Core took place on Tuesday, December 10, 2019, at the University of Texas Health Science Center at Houston (UTHealth – Houston). Speakers highlighted the core’s capacities and provided examples of successful core collaborations.
On January 10, 2020, Dr. Zhiqiang An was inducted into the University of Kentucky College of Agriculture, Food and Environment Hall of Distinguished Alumni. The award, honoring Dr. An’s contributions as a leader in the field of antibody engineering for cancer therapies, is the highest alumni award the college bestows.
Results of a Therapeutic Antibody Core collaborative project with Dr. Philipp Scherer were published in a Cell Metabolism article.